Cowen restated their hold rating on shares of Emergent Biosolutions (NYSE:EBS) in a research report report published on Thursday, AnalystRatings.com reports. The brokerage currently has a $67.00 price objective on the biopharmaceutical company’s stock.
EBS has been the topic of several other research reports. Laidlaw set a $72.00 target price on shares of Emergent Biosolutions and gave the company a buy rating in a report on Wednesday, September 4th. Chardan Capital set a $71.00 target price on shares of Emergent Biosolutions and gave the company a buy rating in a report on Tuesday, September 3rd. Guggenheim assumed coverage on shares of Emergent Biosolutions in a report on Thursday, September 12th. They set a buy rating and a $65.00 target price on the stock. ValuEngine raised shares of Emergent Biosolutions from a hold rating to a buy rating in a report on Wednesday, September 4th. Finally, Wells Fargo & Co raised shares of Emergent Biosolutions from a market perform rating to an outperform rating and increased their target price for the company from $61.00 to $64.00 in a report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $69.00.
Emergent Biosolutions stock traded down $0.96 during midday trading on Thursday, reaching $54.04. 350,011 shares of the stock were exchanged, compared to its average volume of 451,394. The company’s fifty day moving average is $54.01 and its 200-day moving average is $48.08. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.53 and a current ratio of 2.30. The firm has a market cap of $3.00 billion, a PE ratio of 23.19, a PEG ratio of 0.96 and a beta of 1.55. Emergent Biosolutions has a 52 week low of $39.11 and a 52 week high of $73.89.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.58. The firm had revenue of $311.80 million for the quarter, compared to analyst estimates of $289.16 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The business’s revenue for the quarter was up 79.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.55 EPS. On average, sell-side analysts anticipate that Emergent Biosolutions will post 3.04 earnings per share for the current fiscal year.
In related news, Director Kathryn C. Zoon sold 1,509 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $56.12, for a total transaction of $84,685.08. Following the transaction, the director now owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 14.10% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Earnest Partners LLC raised its position in shares of Emergent Biosolutions by 860.6% in the second quarter. Earnest Partners LLC now owns 1,692,171 shares of the biopharmaceutical company’s stock valued at $81,749,000 after buying an additional 1,516,013 shares during the last quarter. Jennison Associates LLC raised its holdings in Emergent Biosolutions by 197.0% in the second quarter. Jennison Associates LLC now owns 562,121 shares of the biopharmaceutical company’s stock valued at $27,156,000 after acquiring an additional 372,857 shares in the last quarter. Tygh Capital Management Inc. raised its holdings in Emergent Biosolutions by 211.1% in the third quarter. Tygh Capital Management Inc. now owns 298,488 shares of the biopharmaceutical company’s stock valued at $15,605,000 after acquiring an additional 202,527 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Emergent Biosolutions by 119.5% in the second quarter. Wells Fargo & Company MN now owns 344,191 shares of the biopharmaceutical company’s stock valued at $16,628,000 after acquiring an additional 187,359 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Emergent Biosolutions by 218.1% in the second quarter. Morgan Stanley now owns 270,769 shares of the biopharmaceutical company’s stock valued at $13,081,000 after acquiring an additional 185,660 shares in the last quarter. 87.75% of the stock is owned by institutional investors and hedge funds.
About Emergent Biosolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Recommended Story: What are the Benefits of Index Funds?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.